Indian drug maker  Glenmark Pharmaceuticals, which was granted US FDA approval for its combination drug nasal spray Ryaltris early this week, said its Swiss-subsidiary, Glenmark Specialty, has entered into an exclusive licensing agreement with Lotus International Pte. Ltd., a wholly owned subsidiary of Lotus Pharmaceutical Co., for commercialising the product in Singapore, Hong Kong and Vietnam markets. Ryaltris is a novel, fixed-dose combination nasal spray of anti-histamine olopatadine hydrochloride and a steroid – mometasone furoate, indicated for treatment of symptoms associated with allergic rhinitis (AR) in adults and pediatric patients, 12 years of age and older.